TY - JOUR T1 - Cardiovascular comorbidities of COPD in never-smokers JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - 4442 AU - Stig Hagstad AU - Helena Backman AU - Anne Lindberg AU - Eva Rönmark AU - Bo Lundbäck AU - Anders Bjerg Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/4442.abstract N2 - Background: Cardiovascular comorbidities are common in COPD. Smoking is a major determinant of both COPD and cardiovascular disease. The prevalence of comorbidities among never-smokers with COPD is largely unknown.Aim: To study the prevalence of cardiovascular comorbidities in never-smokers with COPD.Methods: Pooled data from three cross-sectional surveys of the Obstructive Lung Disease in Northern Sweden (OLIN) Study was used. 3963 subjects with valid spirometric data were included, of them 1609 were never-smokers. COPD was defined according to GOLD using post-bronchodilator spirometry.Results: 681 (17.2%) of all subjects had COPD, 361 (9.1%) had GOLD stage ≥2. Among never-smokers the corresponding figures were 150 (9.3%) and 71 (4.4%). Adjusted for sex and age, GOLD stage ≥2 in never-smokers was associated with having any cardiovascular disease, OR 1.90 (1.12-3.24). In never-smokers with no COPD, GOLD stage 1 and stage ≥2 respectively, any cardiac disease was seen in 20.2%, 20.3% and 32.4% (p=0.028) compared to 22.4%, 25.2% and 33.8% (p<0.001) in the corresponding groups of ever-smokers. Prevalence of hypertension in never-smokers in the respective groups was 33.4%, 48.1% and 53.5% (p<0.001) compared to 33.2%, 32.8% and 44.4% (p=0.001) in ever-smokers. Similar patterns were seen for anti-hypertensive and cardiac medications in never- and ever-smokers with COPD.Conclusions: In never-smokers COPD GOLD stage ≥2 was associated with cardiovascular comorbidities independently of sex and age. The prevalence of cardiovascular comorbidities by GOLD stage was similar in never- and ever-smoking subjects. Physicians treating COPD patients should consider cardiovascular comorbidities also in subjects with no smoking history. ER -